Form 4: Precigen Director Sells Over $600K in Stock

Jeffrey B. Kindler, a Director at Precigen, Inc., sold 174,360 shares of common stock for over $600,000 through pre-scheduled transactions.

Summary

• Jeffrey B. Kindler, a Director of Precigen, Inc. (PGEN), reported the sale of common stock.
• On September 29, 2025, Kindler sold 67,523 shares of common stock at a weighted average price of $3.6 per share, totaling approximately $243,082.80.
• On September 30, 2025, Kindler sold an additional 106,837 shares of common stock at a weighted average price of $3.38 per share, totaling approximately $360,959.46.
• The total value of shares sold across both transactions is approximately $604,042.26.
• These transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan for the purchase or sale of equity securities.
• Following these sales, Kindler beneficially owns 346,070 shares of Precigen common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While insider selling can be perceived negatively, the fact that it was conducted under a Rule 10b5-1 plan mitigates the implication that it's a reaction to adverse company-specific news. It's likely for personal financial planning.

Positives

• The sales were conducted under a Rule 10b5-1 plan, indicating they were pre-scheduled and not based on new material non-public information, which can mitigate negative market perception.

Negatives

• A director selling a significant number of shares, even under a 10b5-1 plan, can be perceived negatively by the market as it reduces their direct stake in the company.

Risks

• Market perception of insider selling, even if pre-planned, could lead to short-term downward pressure on the stock price.
• Reduced insider ownership might be interpreted by some investors as a lack of confidence, despite the 10b5-1 plan.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends. Insider sales are a routine part of executive compensation and personal financial planning, especially when conducted under a 10b5-1 plan.

Stakeholder Impact

• Shareholders may interpret the director's sale as a signal, potentially leading to short-term fluctuations in stock price, although the 10b5-1 plan suggests it's not based on new information.

Key Dates

Recommendation

The director's sale of shares, while significant in value, was executed under a pre-arranged 10b5-1 plan. This suggests the transaction is for personal financial planning and diversification rather than a reaction to new, negative company developments. Therefore, it does not necessarily indicate a change in the company's fundamental outlook. Investors should 'hold' and monitor future company performance and other market signals, as this specific insider sale does not provide a strong 'buy' or 'sell' signal on its own.

Keywords

Precigen, PGEN, Insider Sale, Form 4, Jeffrey B. Kindler, Director, Stock Transaction, 10b5-1 Plan